Bictegravir: A Comprehensive Monograph on a Second-Generation Integrase Strand Transfer Inhibitor

Executive Summary

Bictegravir is a potent, second-generation integrase strand transfer inhibitor (INSTI) developed by Gilead Sciences for the treatment of Human Immunodeficiency Virus Type 1 (HIV-1) infection. It represents a significant advancement in antiretroviral therapy, characterized by high efficacy, a high genetic barrier to resistance, and a favorable safety profile. Bictegravir is not available as a standalone agent; it is exclusively formulated as a component of Biktarvy®, a once-daily, single-tablet regimen (STR) that also contains the nucleoside reverse transcriptase inhibitors (NRTIs) emtricitabine (FTC) and tenofovir alafenamide (TAF). This combination provides a complete therapeutic regimen in a single pill.

The molecular mechanism of Bictegravir involves the specific inhibition of the HIV-1 integrase enzyme, a crucial catalyst in the viral replication cycle. By binding to the active site of the integrase-viral DNA complex, Bictegravir blocks the strand transfer step, thereby preventing the integration of the viral genome into the host cell's DNA. This action is highly potent, with in-vitro studies demonstrating nanomolar efficacy against wild-type HIV-1 and, critically, retained activity against many viral strains resistant to first-generation INSTIs.

The pharmacokinetic profile of Bictegravir is well-suited for a once-daily, unboosted regimen. It possesses a long elimination half-life of approximately 17-18 hours and is metabolized through dual pathways—cytochrome P450 3A4 (CYP3A4) and UDP-glucuronosyltransferase 1A1 (UGT1A1)—which provides metabolic redundancy and mitigates the risk of certain drug-drug interactions. Its absorption is minimally affected by food, enhancing patient convenience.

Extensive Phase 3 clinical trials have established the robust efficacy and safety of the Bictegravir-based regimen. In treatment-naïve adults, Biktarvy® demonstrated non-inferiority to contemporary dolutegravir-based regimens, achieving high rates of virologic suppression with no emergent resistance. Similarly, in virologically suppressed patients, switching to Biktarvy® from other stable antiretroviral regimens maintained viral suppression effectively and was well-tolerated, in some cases improving the adverse event profile. The efficacy and safety have been confirmed across diverse patient populations, including women, older adults, adolescents, children, and individuals with mild-to-moderate renal impairment.

The safety profile of Biktarvy® is generally favorable, with the most common adverse effects being diarrhea, nausea, and headache. The regimen carries a boxed warning regarding the potential for severe acute exacerbation of hepatitis B upon discontinuation in co-infected patients, a risk attributable to its FTC and TAF components. Key contraindications include co-administration with dofetilide and rifampin.

In summary, Bictegravir, as the cornerstone of the Biktarvy® STR, has become a preferred first-line agent in the management of HIV-1 infection. Its combination of potent antiviral activity, a high barrier to resistance, convenient once-daily dosing without a pharmacokinetic booster, and a well-characterized safety profile positions it as a benchmark against which future antiretroviral innovations are measured.

Section 1: Drug Identification and Physicochemical Properties

This section provides a comprehensive overview of the chemical identity, molecular structure, and fundamental physical characteristics of Bictegravir, establishing the foundational properties of this small molecule antiretroviral agent.

1.1. Nomenclature and Chemical Identifiers

Bictegravir is the International Nonproprietary Name (INN) for this second-generation integrase inhibitor.[1] During its development by Gilead Sciences, it was known by the codename GS-9883.[2] The compound is cataloged under the Chemical Abstracts Service (CAS) Registry Number 1611493-60-7 for the free acid form, while its sodium salt is identified by CAS Number 1807988-02-8.[3]

For unambiguous identification across major chemical and pharmacological databases, Bictegravir is assigned several unique identifiers. These include the DrugBank Accession Number DB11799, the ChEBI (Chemical Entities of Biological Interest) ID CHEBI:172943, and the ChEMBL ID CHEMBL3989866.[5] The definitive chemical name, according to the International Union of Pure and Applied Chemistry (IUPAC) nomenclature, is (1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide.[2]

1.2. Molecular Structure and Formula

The molecular formula for Bictegravir is C21​H18​F3​N3​O5​.[3] This corresponds to a molecular weight of approximately 449.4 g/mol, with minor variations reported across sources (449.39 g/mol, 449.38 g/mol) and a precise exact mass of 449.1199 Da.[2]

Chemically, Bictegravir is classified as a complex organic heterotetracyclic compound. Its structure incorporates several key functional groups, including a monocarboxylic acid amide, a secondary carboxamide, and a trifluorobenzene moiety.[5] The complex, rigid polycyclic core is a sophisticated chemical architecture designed to optimize binding affinity and specificity to the active site of the HIV-1 integrase enzyme. This rigidity helps to minimize the conformational entropy lost upon binding, contributing to a high-affinity interaction. The trifluorobenzyl group is another critical feature; the three highly electronegative fluorine atoms can form strong, specific halogen bonds or hydrogen bonds within the enzyme's binding pocket, further anchoring the molecule and enhancing its inhibitory potency.

For computational and structural database referencing, the molecule is represented by the following standard identifiers:

• InChIKey: SOLUWJRYJLAZCX-LYOVBCGYSA-N [5]
• SMILES: C1C[C@@H]2C[C@H]1N3C@HCN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F

1.3. Physical and Chemical Characteristics

Bictegravir presents as a crystalline solid at room temperature. It is characterized as a weakly acidic, ionisable, and lipophilic molecule, properties that collectively influence its absorption, distribution, and cell permeability. This balance between lipophilicity and the presence of an ionisable group is crucial for its ability to cross cell membranes to reach its intracellular target while maintaining sufficient solubility for formulation. The compound is reported to be soluble in laboratory solvents such as dimethyl sulfoxide (DMSO) and methanol.

Regarding stability, Bictegravir is sufficiently stable to be shipped under ambient temperature conditions. For long-term storage, it should be kept in a dry, dark environment at -20°C, under which it demonstrates stability for at least four years.

Table 1: Chemical and Physical Identifiers of Bictegravir

Identifier Type	Value	Source Snippet(s)
International Nonproprietary Name (INN)	Bictegravir
Developmental Code	GS-9883
DrugBank ID	DB11799
CAS Number (Free Acid)	1611493-60-7
CAS Number (Sodium Salt)	1807988-02-8
Molecular Formula	C21​H18​F3​N3​O5​
Molecular Weight	449.39 g/mol
IUPAC Name	(1S,11R,13R)-5-hydroxy-3,6-dioxo-N-[(2,4,6-trifluorophenyl)methyl]-12-oxa-2,9-diazatetracyclo[11.2.1.02,11.04,9]hexadeca-4,7-diene-7-carboxamide
InChIKey	SOLUWJRYJLAZCX-LYOVBCGYSA-N
SMILES	C1C[C@@H]2C[C@H]1N3CN4C=C(C(=O)C(=C4C3=O)O)C(=O)NCC5=C(C=C(C=C5F)F)F
Physical Form	Crystalline solid
Solubility	Soluble in DMSO, Methanol

Section 2: Molecular Pharmacology and Mechanism of Action

This section details the pharmacological classification, molecular target, and in-vitro antiviral properties of Bictegravir, providing a comprehensive understanding of its mechanism of action and its profile as a potent antiretroviral agent.

2.1. Therapeutic Class: Integrase Strand Transfer Inhibitors (INSTIs)

Bictegravir is a second-generation integrase strand transfer inhibitor (INSTI), the fourth agent to be approved in this class of antiretroviral drugs. Developed by Gilead Sciences, it was structurally derived from the earlier second-generation INSTI, dolutegravir. The INSTI class targets the HIV-1 integrase enzyme, one of the three essential viral enzymes—along with reverse transcriptase and protease—required for the HIV replication cycle. By targeting this enzyme, INSTIs effectively halt a critical step in the establishment of a productive viral infection within the host cell.

2.2. Target and Mechanism: Inhibition of HIV-1 Integrase Strand Transfer

The primary molecular target of Bictegravir is the HIV-1 integrase enzyme. After the virus enters a host T-cell, its RNA is reverse-transcribed into double-stranded DNA. The integrase enzyme then carries out a two-step process: first, 3'-processing, where it cleaves two nucleotides from each 3' end of the viral DNA, and second, strand transfer, where it covalently inserts this processed viral DNA into the host cell's chromosomal DNA. This integration is an irreversible step that converts the host cell into a permanent factory for producing new virions.

Bictegravir exerts its antiviral effect by binding with high affinity to the active site of the integrase enzyme after it has bound to the viral DNA ends, forming a stable enzyme-substrate-inhibitor complex. This action specifically and potently blocks the strand transfer step of the integration process. By preventing the insertion of the provirus into the host genome, Bictegravir effectively terminates the viral replication cycle. The drug is a highly specific inhibitor of this step, demonstrating much weaker activity against the 3'-processing activity of the enzyme. This specificity is quantified by its 50% inhibitory concentration (

IC50​) values: a highly potent IC50​ of 7.5 nM for strand transfer activity, compared to a much weaker IC50​ of 241 nM for 3'-processing activity.

2.3. In-Vitro Antiviral Activity and Potency

Bictegravir demonstrates potent and selective antiretroviral activity in a variety of in-vitro systems. Its IC50​ for inhibiting the strand transfer activity of purified recombinant HIV-1 integrase is consistently measured at 7.5 ± 0.3 nM. This molecular potency translates to powerful antiviral effects in cell-based assays.

The 50% effective concentration (EC50​), which measures the concentration required to inhibit viral replication by half in cell culture, is in the low nanomolar range across different susceptible cell types. In T-cell lines such as MT-2 and MT-4, EC50​ values range from 1.5 to 2.4 nM. Similar potency is observed in primary human T lymphocytes (

EC50​ = 1.5 to 2.5 nM) and monocyte-derived macrophages (EC50​ = 6.6 nM), the primary cellular reservoirs for HIV-1. Bictegravir is broadly active against clinical isolates of HIV-1, including all major subtypes (Groups M, N, and O).

Furthermore, Bictegravir exhibits a high therapeutic index. The 50% cytotoxic concentration (CC50​) is substantially higher than its effective concentration, resulting in high selectivity indices (CC50​/EC50​) of up to 8,700. This wide margin between the concentration needed for antiviral effect and the concentration that causes cellular toxicity underscores its favorable preclinical safety profile.

2.4. Resistance Profile and Activity Against INSTI-Resistant Variants

A defining characteristic of Bictegravir is its high genetic barrier to the development of resistance, a significant advantage for long-term therapy. In-vitro viral breakthrough studies, where the virus is cultured under constant drug pressure, show that the emergence of resistance to Bictegravir is difficult and requires multiple mutations. The identified resistance pathways, such as R263K combined with M50I, or S153F with a transient T66I, result in only minimal reductions in susceptibility to the drug (approximately 3-fold).

Crucially, Bictegravir maintains substantial activity against viral strains that have developed resistance to first-generation INSTIs, such as raltegravir and elvitegravir. It is active against viruses with many of the common single INSTI resistance-associated mutations (RAMs), including Y143R and Q148R. Its resistance profile is similar to that of dolutegravir, but in-vitro studies have shown that Bictegravir's activity profile against INSTI-resistant strains is slightly broader.

Direct comparative studies have revealed that Bictegravir can be significantly more potent than dolutegravir against certain highly resistant viral isolates, particularly those carrying complex mutation patterns like G140S/Q148H. This enhanced activity against resistant variants is not coincidental but a result of specific structural modifications made during its development. These modifications are thought to confer greater conformational flexibility to the Bictegravir molecule, allowing it to adapt more effectively to changes in the shape of the integrase active site caused by resistance mutations. Furthermore, biophysical studies suggest that Bictegravir exhibits a slower dissociation rate (a slower "off-rate") from the integrase-DNA complex of these mutant variants compared to dolutegravir. This slower off-rate means the inhibitor remains bound to its target for a longer duration, sustaining inhibition even in the presence of mutations that would otherwise weaken the binding of other INSTIs. This molecular-level kinetic advantage translates directly into improved antiviral activity against challenging, highly resistant viral strains.

Another key pharmacological advantage is that Bictegravir is an "unboosted" INSTI, meaning its intrinsic pharmacokinetic properties are sufficient to maintain therapeutic concentrations with once-daily dosing without the need for a pharmacokinetic enhancer like ritonavir or cobicistat. This simplifies the regimen, reduces pill burden, and, most importantly, avoids the extensive drug-drug interactions associated with potent CYP3A4 inhibition by boosting agents, making it a "cleaner" and more versatile component of antiretroviral therapy.

Section 3: Pharmacokinetics and Metabolism

This section provides a detailed analysis of the absorption, distribution, metabolism, and excretion (ADME) of Bictegravir. These pharmacokinetic properties are fundamental to its clinical utility, supporting its once-daily dosing schedule and defining its drug interaction profile.

3.1. Absorption and Bioavailability

Following oral administration, Bictegravir is rapidly absorbed from the gastrointestinal tract. The time to reach maximum plasma concentration (Tmax​) is consistently observed to be between 2.0 and 4.0 hours. Bictegravir is classified as a Biopharmaceutics Classification System (BCS) class 2 molecule, which is characterized by low aqueous solubility and high membrane permeability. This profile suggests that its absorption rate may be limited by its dissolution in the gut.

The effect of food on its absorption has been studied. Administration of Biktarvy® with a moderate-fat meal (~600 kcal) or a high-fat meal (~800 kcal) resulted in a modest increase in Bictegravir's area under the concentration-time curve (AUC) by 24% and its maximum concentration (Cmax​) by 13% relative to fasting conditions. These changes are not considered clinically significant, and therefore, the fixed-dose combination can be administered with or without food. This flexibility enhances patient convenience and adherence, as dosing does not need to be timed around meals.

3.2. Distribution and Plasma Protein Binding

Once absorbed into the systemic circulation, Bictegravir exhibits a relatively small volume of distribution (Vd​), approximately 15.6 L in humans. This suggests that the drug is primarily distributed within the plasma and extracellular fluid compartments rather than extensively partitioning into deep tissues.

A defining characteristic of Bictegravir's distribution is its exceptionally high degree of binding to human plasma proteins, principally albumin. Over 99% of the drug in circulation is protein-bound. This high level of protein binding means that only a small fraction of the total drug concentration is free (unbound) and pharmacologically active. The blood-to-plasma concentration ratio is 0.64, indicating that the drug does not preferentially accumulate in red blood cells.

3.3. Metabolic Pathways: Role of CYP3A4 and UGT1A1

Bictegravir is eliminated from the body primarily through hepatic metabolism, with minor contributions from the kidneys. Its clearance is mediated by two major, distinct enzymatic pathways that contribute in roughly equal measure: oxidation via the cytochrome P450 3A4 (CYP3A4) enzyme system and glucuronidation via the UDP-glucuronosyltransferase 1A1 (UGT1A1) enzyme.

This dual metabolic pathway is a critical pharmacological feature. Many drugs rely on a single primary metabolic route for clearance. If that single pathway is blocked by a co-administered inhibitor or accelerated by an inducer, plasma concentrations of the drug can change dramatically, leading to toxicity or therapeutic failure. Because Bictegravir has two major and independent "escape routes" for metabolism, it has built-in metabolic redundancy. The inhibition of just one pathway (e.g., by a moderate CYP3A4 inhibitor) is less likely to cause a clinically significant change in Bictegravir exposure, as the UGT1A1 pathway can compensate to a degree. Consequently, a clinically significant drug interaction generally requires a potent agent that can simultaneously induce or inhibit both CYP3A4 and UGT1A1, such as rifampin (an inducer) or atazanavir (an inhibitor). This characteristic contributes to a more predictable and manageable drug interaction profile compared to compounds reliant on a single metabolic enzyme.

3.4. Elimination and Excretion

The systemic plasma clearance of Bictegravir is low. The drug exhibits a terminal elimination half-life (

t1/2​) of approximately 17.3 to 18.2 hours. This long half-life is a key property that robustly supports a convenient once-daily dosing interval, as it ensures that therapeutic drug concentrations are maintained above the efficacy threshold throughout the entire 24-hour dosing period.

Renal excretion of the unchanged parent drug is a minor elimination pathway, accounting for only about 1% of the administered dose. The majority of the drug is cleared from the body as oxidative and glucuronide metabolites, which are then excreted.

3.5. Pharmacokinetics in Special Populations

The pharmacokinetic profile of Bictegravir has been evaluated in several key populations to ensure its safe and effective use.

• Renal Impairment: Studies in subjects with severe renal impairment (creatinine clearance [CrCl] 15-29 mL/min) showed no clinically relevant differences in Bictegravir pharmacokinetics compared to healthy individuals. However, the fixed-dose combination Biktarvy® is not recommended in patients with CrCl below 30 mL/min, primarily due to the dosing limitations of the emtricitabine and tenofovir alafenamide components in this population.
• Hepatic Impairment: No clinically significant alterations in Bictegravir pharmacokinetics have been observed in patients with mild (Child-Pugh Class A) or moderate (Child-Pugh Class B) hepatic impairment. Consequently, no dose adjustment is required for these patients. The regimen has not been studied in patients with severe (Child-Pugh Class C) hepatic impairment and is therefore not recommended for this group.
• Geriatric Patients: A dedicated pharmacokinetic study in older adults with HIV (median age 57.5 years, range 50-75) demonstrated that key PK parameters, including Cmax​, trough concentration (Ctrough​), and AUC, were similar to those observed in younger, healthy adults. No correlation was found between age and any pharmacokinetic parameter, supporting the use of the standard dose in the geriatric population.
• Pregnancy: The use of antiretrovirals in pregnancy is critical for preventing perinatal transmission, but physiological changes during gestation can significantly alter drug pharmacokinetics. Initial guidelines were cautious about recommending Bictegravir due to a lack of data. A dedicated pharmacokinetic study in pregnant women revealed that, while overall drug exposure (AUC) was approximately 40% lower during the second and third trimesters compared to postpartum levels, the trough plasma concentrations remained consistently and substantially above the protein-adjusted 95% effective concentration ( EC95​) of 162 ng/mL required for viral suppression. This crucial finding demonstrated that despite the lower exposure, the drug levels remained well within the therapeutic window. All study participants maintained 100% virologic suppression at delivery. This evidence provided the necessary reassurance for treatment guidelines to recommend Biktarvy® as an alternative regimen for use during pregnancy, with the advice to monitor viral load closely.

Table 2: Summary of Key Pharmacokinetic Parameters of Bictegravir

Parameter	Value	Comment/Context	Source Snippet(s)
Tmax​ (Time to Peak Concentration)	2.0–4.0 hours	Rapid oral absorption.
Cmax​ (Peak Concentration)	6,150 ng/mL (6.15 µg/mL)	Geometric mean after multiple doses in HIV+ adults.
Ctrough​ (Trough Concentration)	2,610 ng/mL (2.61 µg/mL)	Geometric mean after multiple doses; well above the EC95​ of 162 ng/mL.
AUC (24-hour exposure)	102 µg·h/mL	Mean after multiple doses in HIV+ adults.
Plasma Half-life (t1/2​)	17.3–18.2 hours	Supports a durable once-daily dosing regimen.
Volume of Distribution (Vd​)	15.6 L	Suggests distribution primarily in plasma and extracellular fluid.
Plasma Protein Binding	>99%	Highly bound, primarily to albumin.
Primary Metabolic Pathways	CYP3A4 (Oxidation) and UGT1A1 (Glucuronidation)	Dual pathways provide metabolic redundancy.
Key Excretion Route	Hepatic metabolism; renal excretion of unchanged drug is minor (~1%).	Cleared primarily as metabolites.
Food Effect	Minor increase in AUC (24%) and Cmax​ (13%) with food.	Not clinically significant; can be taken with or without food.

Section 4: Clinical Development and Efficacy in HIV-1 Treatment

This section provides a detailed synthesis of the extensive clinical trial program that established the efficacy, safety, and non-inferiority of the Bictegravir-based single-tablet regimen, Biktarvy®, leading to its regulatory approval and widespread clinical use for the treatment of HIV-1 infection.

4.1. Overview of the Clinical Trial Program

The clinical development of Bictegravir has been comprehensive, encompassing studies across all phases of clinical research. The program began with Phase 1 studies to evaluate initial safety, pharmacokinetics, and antiviral activity (e.g., NCT02275065) and progressed through large-scale, pivotal Phase 3 trials. The program has continued into the post-marketing phase with Phase 4 studies and observational cohorts designed to gather long-term real-world data (e.g., NCT06337032, BICSTaR). In total, the Biktarvy® clinical trial program has enrolled over 3,600 participants, with follow-up data extending up to five years, providing a robust evidence base for its long-term performance.

4.2. Efficacy in Treatment-Naïve Adults: Analysis of Pivotal Trials (Studies 1489 & 1490)

The foundation of Biktarvy's indication for initial antiretroviral therapy (ART) rests on two large, randomized, double-blind, active-controlled Phase 3 trials: Study 1489 and Study 1490. The design of these trials was strategically chosen not to demonstrate superiority over older agents but to establish non-inferiority against the most potent and widely used contemporary regimens, thereby positioning Biktarvy® as a first-line alternative with potential advantages in tolerability and resistance.

• Study 1489 compared once-daily Biktarvy® (BIC/FTC/TAF) to a fixed-dose combination of abacavir/dolutegravir/lamivudine (ABC/DTG/3TC), a then-standard-of-care INSTI-based regimen.
• Study 1490 compared Biktarvy® to a regimen of dolutegravir (DTG) plus a co-formulated backbone of emtricitabine/tenofovir alafenamide (FTC/TAF).

The primary endpoint for both studies was the proportion of participants with plasma HIV-1 RNA levels below 50 copies/mL at Week 48, as determined by the FDA Snapshot algorithm. In both trials, Biktarvy® met the primary endpoint, demonstrating statistical non-inferiority to the dolutegravir-based comparator regimens. High rates of virologic suppression were maintained through long-term follow-up at 96, 144, and up to 5 years, confirming the durability of the regimen. A landmark finding across these and all other pivotal trials was the high barrier to resistance; there were zero cases of treatment-emergent resistance to any of the three components of Biktarvy® through long-term analysis.

4.3. Efficacy in Virologically Suppressed Adults (Switch Studies): Analysis of Pivotal Trials (Studies 1844 & 1878)

Establishing the safety and efficacy of switching from a stable regimen is as critical as demonstrating efficacy in treatment-naïve patients, as it provides an option for regimen simplification and optimization for the majority of people with HIV who are already on treatment. Two key Phase 3 trials evaluated this scenario.

• Study 1844 was a randomized, double-blind study that evaluated the efficacy and safety of switching virologically suppressed adults from a regimen of ABC/DTG/3TC to Biktarvy®. At Week 48, Biktarvy® was found to be non-inferior to continuing the existing regimen in maintaining virologic suppression (HIV-1 RNA <50 copies/mL).
• Study 1878 was a randomized, open-label study that assessed switching from a boosted protease inhibitor (bPI)-based regimen (either atazanavir or darunavir, boosted with ritonavir or cobicistat, plus two NRTIs) to Biktarvy®. Again, Biktarvy® demonstrated non-inferiority to continuing the bPI regimen at Week 48 in maintaining virologic suppression.

In both studies, high rates of virologic suppression were maintained after the switch, with no participants in the Biktarvy® arms developing treatment-emergent resistance. A notable secondary finding from Study 1844 was a significantly lower incidence of drug-related adverse events in the Biktarvy® arm (8%) compared to the ABC/DTG/3TC arm (16%), driven primarily by fewer gastrointestinal and neuropsychiatric side effects like abnormal dreams and insomnia. This demonstrated a tangible tolerability benefit for patients switching to Biktarvy®.

4.4. Clinical Efficacy Across Diverse Patient Populations

The Biktarvy® clinical program was designed to include a broad range of patient populations to ensure its efficacy and safety are generalizable to real-world clinical practice. Consistent efficacy has been demonstrated across various demographics and baseline clinical characteristics.

• Baseline Characteristics: Efficacy was maintained in participants with high baseline viral loads (HIV-1 RNA >100,000 copies/mL) and those with low CD4 T-cell counts (<200 cells/μL) at initiation.
• Women: A dedicated Phase 3 study (Study 1961) exclusively enrolled virologically suppressed women and demonstrated that switching to Biktarvy® was non-inferior to continuing their baseline regimen, confirming its utility in a population historically underrepresented in HIV clinical trials.
• Geriatric Patients: A Phase 3b, open-label trial in virologically suppressed adults aged 65 years and older showed high rates of continued virologic suppression and good tolerability at Week 48, supporting its use in this growing patient demographic.
• Pediatrics and Adolescents: Open-label, single-arm trials have established the safety and efficacy of Biktarvy® in virologically suppressed children and adolescents, leading to its approval for patients weighing at least 14 kg.
• Renal Impairment: Biktarvy® has been studied and is indicated for use in patients with mild-to-moderate renal impairment (estimated CrCl ≥30 mL/min). Furthermore, a study in virologically suppressed adults with end-stage renal disease (ESRD) on chronic hemodialysis demonstrated that Biktarvy® maintained virologic suppression, supporting its use in this complex population.
• Pre-existing Resistance: Biktarvy® has demonstrated efficacy in maintaining virologic suppression in patients with a known or suspected M184V/I resistance mutation, a common mutation that confers high-level resistance to emtricitabine and lamivudine. This is attributed to the high potency of the Bictegravir and tenofovir alafenamide components.

4.5. Ongoing and Future Research

The clinical development of Bictegravir continues as the landscape of HIV treatment evolves. Biktarvy® now serves as a standard-of-care comparator arm in clinical trials evaluating novel, long-acting injectable regimens. Ongoing studies are comparing weekly oral islatravir/lenacapavir to Biktarvy® (NCT06630286) and evaluating a novel two-drug combination of Bictegravir/lenacapavir (NCT06333808). These trials highlight Biktarvy's established position as the benchmark against which future therapeutic strategies are measured.

Table 3: Pivotal Phase 3 Clinical Trials of Biktarvy® (Bictegravir/Emtricitabine/Tenofovir Alafenamide)

Study ID	Patient Population	Study Design	N (Biktarvy® Arm / Comparator Arm)	Comparator Regimen	Primary Endpoint	Key Efficacy Result (% Suppressed at Week 48)	Key Resistance Finding	Source Snippet(s)
Study 1489	Treatment-Naïve Adults	Randomized, Double-Blind, Active-Controlled	314 / 315	Abacavir/Dolutegravir/ Lamivudine (ABC/DTG/3TC)	HIV-1 RNA <50 copies/mL at Week 48	92.4% / 93.0% (Non-inferior)	No treatment-emergent resistance in either arm.
Study 1490	Treatment-Naïve Adults	Randomized, Double-Blind, Active-Controlled	320 / 325	Dolutegravir (DTG) + Emtricitabine/Tenofovir Alafenamide (FTC/TAF)	HIV-1 RNA <50 copies/mL at Week 48	89.4% / 92.9% (Non-inferior)	No treatment-emergent resistance in either arm.
Study 1844	Virologically Suppressed Adults (Switch)	Randomized, Double-Blind, Active-Controlled	282 / 281	Abacavir/Dolutegravir/ Lamivudine (ABC/DTG/3TC)	HIV-1 RNA ≥50 copies/mL at Week 48	1.1% / 0.4% (Non-inferior)	No treatment-emergent resistance in either arm.
Study 1878	Virologically Suppressed Adults (Switch)	Randomized, Open-Label, Active-Controlled	290 / 287	Boosted Protease Inhibitor (bPI) + 2 NRTIs	HIV-1 RNA <50 copies/mL at Week 48	92.1% / 88.9% (Non-inferior)	No treatment-emergent resistance in either arm.

Section 5: Commercial Formulation, Approved Indications, and Dosing

This section details the practical clinical aspects of Bictegravir, including its exclusive formulation, its evolution of approved indications by major regulatory bodies, and specific recommendations for dosing and administration.

5.1. Biktarvy®: A Fixed-Dose Combination Regimen

Bictegravir is not marketed as a standalone medication. It is available exclusively as a component of Biktarvy®, a fixed-dose, single-tablet regimen (STR). This formulation combines three antiretroviral agents from two different drug classes to provide a complete treatment regimen in a single daily pill:

• Bictegravir (BIC): An integrase strand transfer inhibitor (INSTI).
• Emtricitabine (FTC): A nucleoside reverse transcriptase inhibitor (NRTI).
• Tenofovir Alafenamide (TAF): A nucleotide reverse transcriptase inhibitor (NRTI).

This three-drug combination targets multiple stages of the HIV replication cycle, a cornerstone of effective and durable antiretroviral therapy.

5.2. Regulatory Approvals and Official Indications

Biktarvy® has received approval from major regulatory agencies worldwide, and its indication has strategically expanded over time based on accumulating clinical data.

• U.S. Food and Drug Administration (FDA): The initial FDA approval for Biktarvy® was granted on February 7, 2018. The label has since undergone several key expansions:
• Initial Approval (2018): For the treatment of HIV-1 infection in adults who are treatment-naïve or to replace the current antiretroviral regimen in those who are virologically suppressed on a stable regimen.
• Pediatric Expansion (Oct 2021): The indication was expanded to include pediatric patients weighing at least 14 kg.
• Expanded Switch Indication (Feb 2024): The label was updated to include data for virologically suppressed adults with pre-existing M184V/I resistance.
• Pregnancy Data Update (Apr 2024): The label was updated with pharmacokinetic and safety data for use in pregnant individuals.
• Treatment-Experienced, Viremic Indication (July 2025): In a significant expansion, the FDA approved Biktarvy® for people with a history of ART who are not virologically suppressed and are restarting treatment, provided they have no known or suspected resistance to the INSTI class, emtricitabine, or tenofovir. This timeline demonstrates a deliberate lifecycle management strategy, leveraging robust clinical data to systematically broaden the drug's utility from a first-line agent to a versatile option for a wide spectrum of patient scenarios, including more complex, harder-to-treat populations.
• European Medicines Agency (EMA): Marketing authorisation in the European Union was granted on June 21, 2018. The indication is for the treatment of HIV-1 in adults and pediatric patients from 2 years of age and weighing at least 14 kg, in whom the virus has not developed resistance to the INSTI class, tenofovir, or emtricitabine. A lower-dose tablet for pediatric use was subsequently approved in November 2022.

5.3. Dosing and Administration Recommendations

The dosing of Biktarvy® is standardized based on patient weight and is administered once daily.

• Adults and Children Weighing ≥25 kg: The recommended dosage is one tablet taken orally once daily. Each tablet contains 50 mg of Bictegravir, 200 mg of Emtricitabine, and 25 mg of Tenofovir Alafenamide.
• Children Weighing 14 kg to <25 kg: A lower-strength tablet is available for this population, also taken once daily. Each tablet contains 30 mg of Bictegravir, 120 mg of Emtricitabine, and 15 mg of Tenofovir Alafenamide.

Administration Instructions:

• Biktarvy® can be taken with or without food, which provides flexibility for patients.
• For children or patients who are unable to swallow a whole tablet, the tablet can be split, and all parts must be ingested sequentially within approximately 10 minutes to ensure the full dose is administered.
• For patients on chronic hemodialysis, the daily dose of Biktarvy® should be taken after the dialysis session is completed.
• Specific instructions regarding co-administration with polyvalent cation-containing antacids and supplements must be followed to avoid chelation interactions, as detailed in Section 7.

Section 6: Safety, Tolerability, and Risk Management

This section provides a comprehensive analysis of the safety profile of the Bictegravir-based regimen, Biktarvy®, synthesizing data from extensive clinical trials and post-marketing surveillance. It covers common adverse reactions, serious adverse events, and the critical boxed warning associated with the product.

6.1. Overview of the Adverse Event Profile

Across its extensive clinical development program, Biktarvy® has been shown to be generally well-tolerated. The safety profile is a composite of its three active ingredients, and a nuanced understanding requires distinguishing the effects attributable to the novel INSTI (Bictegravir) from the well-established class effects of its NRTI backbone (emtricitabine and tenofovir alafenamide). In comparative switch studies, Biktarvy® demonstrated a favorable tolerability profile, with a lower incidence of drug-related adverse events compared to some comparator regimens, particularly those containing abacavir/dolutegravir/lamivudine.

6.2. Common Adverse Reactions

The most frequently reported adverse drug reactions in clinical trials are generally mild to moderate in severity. These include:

• Gastrointestinal: Diarrhea (3% to 6%) and nausea (3% to 6%).
• Neurological: Headache (4% to 5%).

Other reported adverse events occurring in a smaller percentage of patients include dizziness (2%), fatigue (2% to 3%), insomnia (2%), and abnormal dreams (≤3%).

6.3. Serious Adverse Events and Events of Special Interest

While generally safe, Biktarvy® is associated with several potential serious adverse events, many of which are class effects of its components.

• Renal Effects: Tenofovir prodrugs have been associated with nephrotoxicity. Although tenofovir alafenamide (TAF) has an improved renal safety profile compared to its predecessor, tenofovir disoproxil fumarate (TDF), there remains a risk of new-onset or worsening renal impairment, including rare cases of acute renal failure and Fanconi syndrome. Clinical trials of Biktarvy® reported no cases of Fanconi syndrome or proximal renal tubulopathy. Routine monitoring of renal function, including serum creatinine, estimated CrCl, urine glucose, and urine protein, is recommended for all patients prior to initiation and during therapy.
• Hepatic Events: While Bictegravir itself has a low likelihood of causing hepatotoxicity, mild, transient elevations in alanine aminotransferase (ALT) were observed in approximately 11% of patients in clinical trials, a rate similar to comparator arms. Rare but serious cases of lactic acidosis and severe hepatomegaly with steatosis, which can be fatal, are known class effects associated with NRTIs like FTC and TAF. Two post-marketing cases of drug-induced liver injury, one fatal, have been reported in women who switched to a Bictegravir-containing regimen.
• Immune Reconstitution Inflammatory Syndrome (IRIS): In patients starting any effective ART, a rapid improvement in immune function can lead to an exaggerated inflammatory response to pre-existing, subclinical opportunistic infections (such as Mycobacterium avium complex, cytomegalovirus, or tuberculosis) or the unmasking of autoimmune disorders (such as Graves' disease or Guillain-Barré syndrome). This is a class effect of ART and requires clinical management.
• Other Events of Note: Increases in serum creatine kinase have been observed in 6% to 8% of patients. Weight gain has been reported in adults receiving Biktarvy®, consistent with trends seen with other modern INSTI-based regimens. Rare but serious events reported in post-marketing surveillance or clinical trials include suicidal ideation, drug reaction with eosinophilia and systemic symptoms (DRESS) syndrome, and thrombocytopenia.

6.4. Boxed Warning: Post-Treatment Acute Exacerbation of Hepatitis B

The most significant safety concern and the subject of a boxed warning on the Biktarvy® label is the risk of severe acute exacerbation of hepatitis B virus (HBV) infection upon discontinuation of the drug.

• Mechanism: This risk is not due to Bictegravir but to the emtricitabine (FTC) and tenofovir alafenamide (TAF) components, both of which possess potent activity against HBV in addition to HIV-1. In patients co-infected with HIV-1 and HBV, these agents suppress both viruses. If Biktarvy® is discontinued, the suppression of HBV is abruptly removed, which can lead to a rapid rebound in HBV replication and a subsequent flare of hepatitis, potentially causing severe liver damage, hepatic decompensation, or liver failure.
• Risk Management Strategy: To mitigate this risk, all patients must be tested for the presence of chronic HBV infection before initiating therapy with Biktarvy®. For patients found to be co-infected, it is critical that they do not discontinue Biktarvy® without consulting their healthcare provider. If discontinuation is necessary, these patients require close monitoring of hepatic function with both clinical and laboratory follow-up for at least several months to detect and manage any potential hepatitis flare.

Section 7: Drug Interaction Profile

This section outlines the clinically significant drug-drug and drug-food interactions associated with Bictegravir, providing essential guidance for safe prescribing and patient counseling. The interaction profile is primarily driven by Bictegravir's metabolic pathways and its susceptibility to chelation.

7.1. Contraindicated Medications

Co-administration of Biktarvy® with certain medications is strictly contraindicated due to the high potential for severe adverse events.

• Dofetilide: Bictegravir is an inhibitor of the renal transporters Organic Cation Transporter 2 (OCT2) and Multidrug and Toxin Extrusion Transporter 1 (MATE1). Dofetilide, an antiarrhythmic agent, is cleared by these transporters. Co-administration can lead to increased plasma concentrations of dofetilide, elevating the risk of life-threatening cardiac arrhythmias, including Torsades de Pointes.
• Rifampin: Rifampin is a potent inducer of the primary enzymes responsible for Bictegravir metabolism, CYP3A4 and UGT1A1. Concomitant use will cause a substantial decrease in Bictegravir plasma concentrations, leading to a loss of virologic efficacy, potential treatment failure, and the development of drug resistance.

7.2. Interactions via CYP3A4 and UGT1A1 Pathways

As Bictegravir is a substrate for both CYP3A4 and UGT1A1, its exposure can be significantly altered by drugs that strongly affect these pathways.

• Strong Inducers: In addition to the contraindicated rifampin, co-administration with other potent dual inducers is not recommended. This includes several anticonvulsants (carbamazepine, oxcarbazepine, phenobarbital, phenytoin) and the herbal supplement St. John's Wort (Hypericum perforatum). These agents can significantly reduce Bictegravir concentrations and compromise its therapeutic effect.
• Strong Inhibitors: Conversely, potent inhibitors of both CYP3A4 and UGT1A1 can significantly increase Bictegravir concentrations. Co-administration with atazanavir, a potent dual inhibitor, is not recommended due to this risk.

7.3. Chelation Interactions with Polyvalent Cations

This is a well-established class effect for all integrase inhibitors, including Bictegravir. Polyvalent cations, such as magnesium (Mg2+), aluminum (Al3+), calcium (Ca2+), and iron (Fe2+/Fe3+), commonly found in antacids, laxatives, and mineral supplements, can bind to (chelate) the INSTI molecule in the gastrointestinal tract. This forms an insoluble complex that prevents the drug's absorption, leading to significantly reduced bioavailability and subtherapeutic plasma levels.

The management of this interaction is based on separating the administration times of Biktarvy® and the cation-containing product. The specific instructions depend on the presence of food, which reflects an interplay between gastrointestinal physiology and the drug's absorption kinetics. While separating doses allows Bictegravir to be absorbed before the cation is introduced, taking certain supplements with food provides a practical alternative. Food delays gastric emptying and can enhance the absorption of lipophilic, low-solubility drugs like Bictegravir. This food-induced enhancement of absorption can partially counteract the reduction caused by chelation, allowing for simultaneous administration in some cases.

• Management:
• Antacids containing aluminum or magnesium: Biktarvy® should be taken at least 2 hours before or 6 hours after these products.
• Supplements containing iron or calcium: Biktarvy® and the supplement can be taken simultaneously if administered with food. Alternatively, if taken under fasting conditions, Biktarvy® should be administered at least 2 hours before the supplement.

7.4. Bictegravir as an Inhibitor/Inducer

At clinically relevant plasma concentrations, Bictegravir itself is not a significant inhibitor or inducer of major CYP450 enzymes or UGT1A1. This contributes to its relatively "clean" profile in terms of affecting the metabolism of other drugs. Its clinically relevant inhibitory activity is limited to the OCT2 and MATE1 transporters, as noted above with dofetilide and also relevant for drugs like metformin, although metformin does not typically require a dose adjustment in patients with normal renal function.

Table 4: Clinically Significant Drug Interactions with Bictegravir

Interacting Drug/Class	Mechanism of Interaction	Effect on Bictegravir/Other Drug	Clinical Recommendation	Source Snippet(s)
Dofetilide	Inhibition of OCT2/MATE1 by Bictegravir	Increased dofetilide concentration	Contraindicated due to risk of life-threatening cardiac arrhythmia.
Rifampin	Potent induction of CYP3A4 and UGT1A1	Significantly decreased Bictegravir concentration	Contraindicated due to risk of virologic failure and resistance.
St. John's Wort	Potent induction of CYP3A4 and UGT1A1	Significantly decreased Bictegravir concentration	Co-administration is not recommended.
Strong Anticonvulsants (Carbamazepine, Phenytoin, etc.)	Induction of CYP3A4 and UGT1A1	Decreased Bictegravir concentration	Co-administration is not recommended.
Polyvalent Cation Antacids (Mg, Al)	Chelation in GI tract	Decreased Bictegravir absorption	Administer Biktarvy® at least 2 hours before or 6 hours after antacid.
Calcium/Iron Supplements	Chelation in GI tract	Decreased Bictegravir absorption	Administer simultaneously with food, OR administer Biktarvy® at least 2 hours before supplement (on empty stomach).
Atazanavir	Potent inhibition of CYP3A4 and UGT1A1	Increased Bictegravir concentration	Co-administration is not recommended.
Rifabutin	Induction of CYP3A and P-gp	Decreased Bictegravir concentration	Co-administration is not recommended.

Section 8: Conclusion: Bictegravir's Role in Modern Antiretroviral Therapy

Bictegravir, as the integrase strand transfer inhibitor component of the single-tablet regimen Biktarvy®, has firmly established itself as a cornerstone of modern antiretroviral therapy for HIV-1 infection. Its clinical and pharmacological profile addresses the primary goals of long-term HIV management: potent and durable virologic suppression, a high barrier to the development of drug resistance, excellent long-term safety and tolerability, and a simplified, convenient dosing regimen that promotes patient adherence.

Major international treatment guidelines, including those from the U.S. Department of Health and Human Services (DHHS), recommend Biktarvy® as a preferred first-line option for most people with HIV. This recommendation is built upon a robust foundation of evidence from a comprehensive clinical trial program that demonstrated non-inferiority to the most potent contemporary regimens in both treatment-naïve and virologically suppressed patients. The consistent finding of zero treatment-emergent resistance in pivotal trials is a particularly compelling feature, offering reassurance for lifelong therapy.

The success of Bictegravir can be attributed to a confluence of favorable attributes. Its molecular design confers high potency against both wild-type and certain INSTI-resistant HIV-1 variants. Its pharmacokinetic profile, characterized by a long half-life and dual metabolic pathways, supports a convenient once-daily, unboosted regimen with a manageable drug interaction profile. The extensive clinical data have confirmed its efficacy and safety across an increasingly diverse range of patient populations, from children and adolescents to older adults, pregnant individuals, and those with certain comorbidities. The progressive expansion of its approved indications further solidifies its role as a versatile agent suitable for a wide spectrum of clinical scenarios.

While Biktarvy® represents a pinnacle of achievement in daily oral antiretroviral therapy, the field continues to advance. The emergence of novel long-acting injectable agents marks the next frontier in HIV treatment, aiming to further reduce treatment burden. In this evolving landscape, the high efficacy, durability, and safety of the Bictegravir-based regimen serve as the critical benchmark against which these future innovations will be rigorously evaluated. Therefore, Bictegravir is not only a leading therapeutic agent of the present but also a key standard for the future of HIV care.

Works cited

1. Bictegravir - Wikipedia, accessed September 10, 2025, https://en.wikipedia.org/wiki/Bictegravir
2. Bictegravir - BioGems, accessed September 10, 2025, https://www.bio-gems.com/bictegravir.html
3. Bictegravir | CAS#1611493-60-7 | HIV-1 Inhibitor - MedKoo Biosciences, accessed September 10, 2025, https://www.medkoo.com/products/10584
4. Bictegravir | 99.93%(HPLC) | In Stock | Integrase inhibitor - Selleck Chemicals, accessed September 10, 2025, https://www.selleckchem.com/products/bictegravir.html
5. Bictegravir | C21H18F3N3O5 | CID 90311989 - PubChem, accessed September 10, 2025, https://pubchem.ncbi.nlm.nih.gov/compound/Bictegravir
6. Bictegravir (GS-9883, CAS Number: 1611493-60-7) | Cayman Chemical, accessed September 10, 2025, https://www.caymanchem.com/product/26532/bictegravir
7. Full article: Human pharmacokinetics prediction with an in vitro–in vivo correction factor approach and in vitro drug-drug interaction profile of bictegravir, a potent integrase-strand transfer inhibitor component in approved biktarvy® for the treatment of HIV-1 infection - Taylor & Francis Online, accessed September 10, 2025, https://www.tandfonline.com/doi/full/10.1080/00498254.2023.2169207
8. Bictegravir - LiverTox - NCBI Bookshelf, accessed September 10, 2025, https://www.ncbi.nlm.nih.gov/books/NBK547914/
9. www.ncbi.nlm.nih.gov, accessed September 10, 2025, [https://www.ncbi.nlm.nih.gov/books/NBK547914/#:~:text=Bictegravir%20(bic%20teg'%20ra%20vir,provirus%20into%20the%20host%20genome.](https://www.google.com/url?q=https://www.ncbi.nlm.nih.gov/books/NBK547914/%23:~:text%3DBictegravir%2520(bic%2520teg'%2520ra%2520vir,provirus%2520into%2520the%2520host%2520genome.&sa=D&source=editors&ust=1757499453476669&usg=AOvVaw0LGrgOWOaJrVTAOEhpiTtF)
10. Bictegravir: Uses, Interactions, Mechanism of Action | DrugBank Online, accessed September 10, 2025, https://go.drugbank.com/drugs/DB11799
11. Bictegravir, Emtricitabine, and Tenofovir Alafenamide | Drug Lookup | Pediatric Care Online, accessed September 10, 2025, https://publications.aap.org/pediatriccare/drug-monograph/18/6233/Bictegravir-Emtricitabine-and-Tenofovir
12. Bictegravir (GS-9883) | HIV-1 Integrase Inhibitor | MedChemExpress, accessed September 10, 2025, https://www.medchemexpress.com/Bictegravir.html
13. Bictegravir/Emtricitabine/Tenofovir Alafenamide: A Review in HIV-1 Infection - PMC, accessed September 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC6424950/
14. Antiviral Activity, Safety, and Pharmacokinetics of Bictegravir as 10-Day Monotherapy in HIV-1–Infected Adults - PMC, accessed September 10, 2025, https://pmc.ncbi.nlm.nih.gov/articles/PMC5389589/
15. Bictegravir PK Fact Sheet, accessed September 10, 2025, https://liverpool-hiv-hep.s3.amazonaws.com/prescribing_resources/pdfs/000/000/169/original/HIV_FactSheet_BIC_2018_Oct.pdf?1632406430
16. Appendix A: Pediatric Antiretroviral Drug Information - Bictegravir | NIH - Clinical Info HIV.gov, accessed September 10, 2025, https://clinicalinfo.hiv.gov/en/guidelines/pediatric-arv/bictegravir
17. Pharmacokinetics of Bictegravir in Older Japanese People Living with HIV-1 - ASM Journals, accessed September 10, 2025, https://journals.asm.org/doi/10.1128/spectrum.05079-22
18. Bictegravir, emtricitabine, and tenofovir alafenamide (oral route) - Side effects & dosage, accessed September 10, 2025, https://www.mayoclinic.org/drugs-supplements/bictegravir-emtricitabine-and-tenofovir-alafenamide-oral-route/description/drg-20444471
19. Bictegravir's pharmacokinetics appear promising for ART in pregnancy - IDSA, accessed September 10, 2025, https://www.idsociety.org/science-speaks-blog/2023/bictegravirs-pharmacokinetics-appear-promising-for-art-in-pregnancy/
20. US FDA Approves New Biktarvy Indication For People With HIV Who Are Treatment Experienced And Restarting Antiretroviral Treatment - Gilead Sciences, accessed September 10, 2025, https://www.gilead.com/company/company-statements/2025/us-fda-approves-new-biktarvy-indication-for-people-with-hiv-who-are-treatment-experienced-and-restarting-antiretroviral-treatment
21. Bictegravir Completed Phase 1 Trials for Human Immunodeficiency Virus Type 1 (HIV-1) Infection Treatment - DrugBank, accessed September 10, 2025, https://go.drugbank.com/drugs/DB11799/clinical_trials?conditions=DBCOND0045921&phase=1&purpose=treatment&status=completed
22. Bictegravir Recruiting Phase 4 Trials for Human Immunodeficiency Virus Type 1 (HIV-1) Infection Treatment - DrugBank, accessed September 10, 2025, https://go.drugbank.com/drugs/DB11799/clinical_trials?conditions=DBCOND0045921&phase=4&purpose=treatment&status=recruiting
23. BIKTARVY® Clinical Trial Experience | Official HCP Site, accessed September 10, 2025, https://www.biktarvyhcp.com/efficacy-resistance/clinical-trial-experience
24. BIKTARVY® HIV Treatment Proven by Clinical Studies, accessed September 10, 2025, https://www.biktarvy.com/about-biktarvy/efficacy-effectiveness
25. For HCP's | Biktarvy® (BIC/FTC/TAF) Use in Baseline PI Resistance, accessed September 10, 2025, https://www.askgileadmedical.com/docs/biktarvy/biktarvy-use-in-baseline-pi-resistance
26. U.S. Food and Drug Administration Approves Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for Treatment of HIV-1 Infection, accessed September 10, 2025, https://www.gilead.com/news/news-details/2018/us-food-and-drug-administration-approves-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-treatment-of-hiv-1-infection
27. Gilead Presents Results from Phase 3 Study Evaluating Patients ..., accessed September 10, 2025, https://www.gilead.com/news/news-details/2018/gilead-presents-results-from-phase-3-study-evaluating-patients-who-switched-to-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-from-regimen-containing-abacavir-dolutegravir-and-
28. Gilead Presents Data From Phase 3 Study Evaluating Women Who Switched to Biktarvy® (Bictegravir, Emtricitabine and Tenofovir Alafenamide) From a Boosted Protease Inhibitor-Based Regimen or Boosted Elvitegravir-Containing Regimen, accessed September 10, 2025, https://www.gilead.com/news/news-details/2018/gilead-presents-data-from-phase-3-study-evaluating-women-who-switched-to-biktarvy-bictegravir-emtricitabine-and-tenofovir-alafenamide-from-a-boosted-protease-inhibitor-based-regimen-or-boost
29. Biktarvy | European Medicines Agency (EMA), accessed September 10, 2025, https://www.ema.europa.eu/en/medicines/human/EPAR/biktarvy
30. Bictegravir Active Not Recruiting Phase 3 Trials for Human Immunodeficiency Virus Type 1 (HIV-1) Infection Treatment - DrugBank, accessed September 10, 2025, https://go.drugbank.com/drugs/DB11799/clinical_trials?conditions=DBCOND0045921&phase=3&purpose=treatment&status=active_not_recruiting
31. Bictegravir - brand name list from Drugs.com, accessed September 10, 2025, https://www.drugs.com/ingredient/bictegravir.html
32. How Biktarvy works: Mechanism of action explained - Medical News Today, accessed September 10, 2025, https://www.medicalnewstoday.com/articles/drugs-how-biktarvy-works
33. Introduction - Clinical Review Report: Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/FTC/TAF) (Biktarvy) - NCBI Bookshelf, accessed September 10, 2025, https://www.ncbi.nlm.nih.gov/books/NBK539532/
34. Biktarvy (bictegravir, emtricitabine and tenofovir alafenamide) FDA Approval History, accessed September 10, 2025, https://www.drugs.com/history/biktarvy.html
35. FDA approves expanded indication for Biktarvy for HIV treatment in young children | EATG, accessed September 10, 2025, https://www.eatg.org/hiv-news/fda-approves-expanded-indication-for-biktarvy-for-hiv-treatment-in-young-children/
36. Human medicines European public assessment report (EPAR): Biktarvy, bictegravir,emtricitabine,tenofovir alafenamide, Date of authorisation: 21/06/2018, Revision: 18, Status, accessed September 10, 2025, https://efim.org/node/143195
37. European Commission Grants Marketing Authorization for Gilead's Biktarvy® (Bictegravir, Emtricitabine, Tenofovir Alafenamide) for the Treatment of HIV-1 Infection, accessed September 10, 2025, https://www.gilead.com/news/news-details/2018/european-commission-grants-marketing-authorization-for-gileads-biktarvy-bictegravir-emtricitabine-tenofovir-alafenamide-for-the-treatment-of-hiv-1-infection
38. First paediatric EC approval of HIV drug - European Pharmaceutical Review, accessed September 10, 2025, https://www.europeanpharmaceuticalreview.com/news/176974/first-paediatric-eu-approval-of-hiv-drug-biktarvy/
39. Patient Information BIKTARVY® (bik-TAR-vee ... - Gilead Sciences, accessed September 10, 2025, https://www.gilead.com/-/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_patient_pi.pdf
40. Bictegravir, Emtricitabine, and Tenofovir Alafenamide: MedlinePlus Drug Information, accessed September 10, 2025, https://medlineplus.gov/druginfo/meds/a618012.html